All news

Denosumab delays metastases in castrate-resistant prostate cancer

Added: Wednesday 2 November 2011

The monoclonal antibody Denosumab has been shown in a recent analysis to delay bone metastases in patients with castrate-resistant prostate cancer. Unfortunately, the results did not amount to an overall survival advantage, though there are tangible quality-of-life benefits.